BioSpecifics Technologies Corp (BSTC) financial statements (2020 and earlier)

Company profile

Business Address 35 WILBUR ST
LYNBROOK, NY 11563
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments89815949332113
Cash and cash equivalents513755106
Short-term investments8468524428117
Receivables191754345
Capitalized contract cost 0
Deferred costs  2111 
Prepaid expense and other current assets0
Income taxes receivable0
Other undisclosed current assets1111000
Total current assets:109986655382518
Noncurrent Assets
Operating lease, right-of-use asset0
Long-term investments and receivables1716441 
Long-term investments1716441 
Intangible assets, net (including goodwill)1000000
Intangible assets, net (excluding goodwill)1000000
Deferred costs  12333
Other undisclosed noncurrent assets 023111
Total noncurrent assets:17299765
TOTAL ASSETS:1271007565463123
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1211111
Accrued liabilities020000 
Employee-related liabilities0000000
Taxes payable0 0    
Other undisclosed accounts payable and accrued liabilities0001000
Debt0      
Deferred revenue and credits11000
Other undisclosed current liabilities0100000
Total current liabilities:1322111
Noncurrent Liabilities
Long-term debt and lease obligation0      
Operating lease, liability0
Liabilities, other than long-term debt1 56000
Deferred revenue and credits56000
Deferred income tax liabilities1
Total noncurrent liabilities:1 56000
Total liabilities:2378111
Stockholders' equity
Stockholders' equity attributable to parent124986856453022
Common stock0000000
Treasury stock, value(12)(11)(8)(7)(6)(4)(4)
Additional paid in capital39363333322521
Retained earnings9772423119105
Total stockholders' equity:124986856453022
TOTAL LIABILITIES AND EQUITY:1271007565463123

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net2726231414
Gross profit:38332726231414
Operating expenses(10)(10)(10)(9)(8)(8)(7)
Other undisclosed operating income     10
Operating income:282318171478
Nonoperating income2110000
Investment income, nonoperating2110000
Other nonoperating income (expense)(0)00000 
Income from continuing operations before income taxes:302518171578
Income tax expense(6)(5)(7)(6)(5)(2)(3)
Net income available to common stockholders, diluted:242011111055

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income:242011111055
Comprehensive income, net of tax, attributable to parent:242011111055

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: